drugset / Trial / NCT05602129

A Clinical Study to Evaluate the Efficacy, Safety and PK/PD Profiles of Anticoagulation of HSK36273 for Injection in Continuous Renal Replacement Therapy Subjects

NCT05602129

Phase 2 Unknown 156 enrolled Haisco Pharmaceutical Group Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is divided into Stage I and Stage II. It is planned to include 156 subjects who need CRRT treatment for more than 48 hours.

Timeline

Start
2022-11
Primary completion
2023-10
Completion
2023-10

Drugs

EvaluationDrugModalityDoseRoute
Subject HSK36273 Unknown
Comparator Heparin Other / unclassified

Indications

No indication recorded.